The lungs from IPF, COPD, and control groups were subjected to a normalized MC density assessment and in-depth head-to-head MC CPA3 comparisons to gain further insight into the characteristic features of CPA3 expression in the respective disease. This evidence concerns the gene CPA3 and chronic obstructive pulmonary disease.